Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Employees: 125,000
0
Funds holding %
of 7,245 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
14% more funds holding in top 10
Funds holding in top 10: 72 [Q4 2024] → 82 (+10) [Q1 2025]
2% more repeat investments, than reductions
Existing positions increased: 1,004 | Existing positions reduced: 981
0.96% less ownership
Funds ownership: 88.16% [Q4 2024] → 87.21% (-0.96%) [Q1 2025]
3% less first-time investments, than exits
New positions opened: 148 | Existing positions closed: 153
3% less funds holding
Funds holding: 2,565 [Q4 2024] → 2,497 (-68) [Q1 2025]
7% less capital invested
Capital invested by funds: $177B [Q4 2024] → $164B (-$13.2B) [Q1 2025]
11% less call options, than puts
Call options by funds: $961M | Put options by funds: $1.08B
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$470
19%
upside
Avg. target
$552
39%
upside
High target
$637
61%
upside
10 analyst ratings
7 positive
70%
3 neutral
30%
0 negative
0%
Argus Research David Toung | 19%upside $470 | Buy Maintained | 29 Apr 2025 |
Scotiabank Sung Ji Nam | 53%upside $605 | Sector Perform Maintained | 25 Apr 2025 |
RBC Capital Conor McNamara | 61%upside $637 | Outperform Maintained | 24 Apr 2025 |
UBS Dan Leonard | 26%upside $500 | Buy Maintained | 24 Apr 2025 |
Stifel Daniel Arias | 56%upside $620 | Buy Maintained | 24 Apr 2025 |
Financial journalist opinion
Based on 21 articles about TMO published over the past 30 days
Neutral
Business Wire
2 hours ago
Thermo Fisher Scientific Introduces Next Generation TruNarc Handheld Narcotics Analyzers to Support Public Safety
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ TruNarc™ Delta and Tau Handheld Narcotics Analyzers* to help communities combat known and emerging narcotics and illicit substances. With touchless technology and an expanded chemical library, the user-friendly devices empower frontline law enforcement officials to identify more than 1,200 substances in the field, including stimulants, depressants, hallucinogen.
Neutral
Business Wire
19 hours ago
Thermo Fisher Scientific Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on July 15, 2025, to shareholders of record as of June 13, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier.
Neutral
Seeking Alpha
1 week ago
Thermo Fisher Scientific Inc. (TMO) BofA Securities 2025 Healthcare Conference (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:40 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Michael Ryskin - Bank of America Michael Ryskin To kick things off, my name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and I'm excited to welcome everyone to Las Vegas for our Healthcare Conference 2025 edition.
Negative
Seeking Alpha
1 week ago
Thermo Fisher: Tariffs Hit, Valuation Compensates
The macro environment has clearly deteriorated, with tariffs and U.S. policy weighing on short-term earnings. Management revised EPS down ~$1, but revenue guidance held as pricing and FX helped offset volume pressure. Tariff-related headwinds are expected to be fully mitigated by 2026 through supply chain adjustments.
Positive
Seeking Alpha
2 weeks ago
10 Undervalued Dividend Growth Stocks: May 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.
Neutral
Business Wire
2 weeks ago
Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 11:40 a.m. (ET). The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in s.
Positive
Seeking Alpha
3 weeks ago
3 Of The Cheapest High-Quality Stocks Money Can Buy
Geopolitical risks and economic uncertainty have battered markets, but I view this turmoil as an opportunity to buy high-quality, undervalued stocks. Despite volatility and weak earnings trends, I'm focused on companies trading well below fair value, with strong fundamentals and long-term growth potential. In this article, I highlight three dirt-cheap stocks across different industries that I believe can deliver significant returns in the years ahead.
Positive
Seeking Alpha
3 weeks ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.
Neutral
Business Wire
3 weeks ago
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities within pre-clinical biologic drug development. The new CHO K-1 cell line is able to deliver up to 8g/L, providing higher protein expression levels and increased.
Positive
Benzinga
3 weeks ago
Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan
Thermo Fisher Scientific Inc. TMO announced Thursday that it would invest an additional $2 billion in the U.S. over the next four years.
Charts implemented using Lightweight Charts™